Specific inhibitors for vascular endothelial growth factor receptors

A compound of formula I or a stereoisomer or pharmaceutically acceptable salt thereof:

• wherein:
• ring A is selected from phenyl, pyridyl, and pyrimidyl;
• ring A is substituted with 0-1 groups selected from O—C7-20 alkyl, O—C7-20 alkenyl, and O—C7-20 alkynyl;
• ring A is substituted with 0-3 groups selected from halogen, NO2, NRaRb, —CN, C1-2 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, CHO, C(O)C1-6 alkyl, CO2—C1-6 alkyl, C(O)NRaRb, S(O)2NRaRb, S(O)p—C1-6 alkyl, phenyl, benzyl, and C3-6 cycloalkyl;
• ring A is substituted with 0-1 groups selected from methylene-dioxyl (—OCH2O—) and ethylene-dioxyl (—OCH2CH2O—);
• L is a linear chain selected from n-propylene, n-butylene, and n-pentylene, wherein
• (a) from 0-2 of the methylene units are replaced by C═O;
• (b) from 0-3 methylene units of L are replaced with a heteroatom selected from O, N, and S(O)p, provided that at least one methylene is present and other than an N—O or O—O bond is formed within L or at either attachment point of L;
• and,
• (c) from 0-1 double bonds are present between the chain atoms of L;
• L is substituted with 0-2 groups selected from C1-4 alkyl, phenyl, benzyl, C3-6 cycloalkyl, and NRaRb;
• alternatively, when L is 4-5 atoms in length, then three of the chain atoms optionally combine with a 2 atom bridge to form a 5 membered ring, the ring consisting of carbon atoms and 0-2 heteroatoms selected from O, N, and S(O)p, wherein the ring has 0-2 ring double bonds and from 0-1 atom of the 2 atom bridge is replaced by as carbonyl group;
• alternatively, a carbon atom in ring A that is adjacent to the carbon atom to which linker L is attached can be attached to linker L through a (CH2)1-2 bridge to form a 5-6 membered ring, wherein optionally 1 methylene of the bridge is replaced by a carbonyl group;
• Ra and Rb are independently at each occurrence selected from H and C1-6 alkyl;
• alternatively, independently at each occurrence, NRaRb forms a 5-6 membered cyclic amine consisting of the shown nitrogen atom and 4-5 methylenes;
• ring B is selected from phenyl, pyridyl, pyrimidyl, and
• wherein the phenyl, pyridyl, and pyrimidyl rings are substituted with 1-3 R groups;
• R is independently selected from CO2H, halogen, NO2, NRaRb, —CN, C1-2 haloalkyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, CHO, C(O)C1-6 alkyl, CO2—C1-6 alkyl, C(O)NRaRb, S(O)2NRaRb, S(O)p—C1-6 alkyl, C3-6 cycloalkyl, phenyl substituted with 0-2 R1 groups, benzyl substituted with 0-2 R1 groups, S-phenyl substituted with 0-2 R1 groups, O-phenyl substituted with 0-2 R1 groups, and NRa-phenyl substituted with 0-2 R1 groups;
• alternatively, ring B is substituted with 0-1 groups selected from methylene-dioxyl (—OCH2O—) and ethylene-dioxyl (—OCH2CH2O—);
• R1 is independently selected from CO2H, halogen, NH2, C1-2 haloalkyl, C1-6 alkyl, C1-6 alkoxy, C(O)C1-6 alkyl, and CO2C1-6 alkyl;
• and,
• p is independently selected from 0, 1, and 2;
• provided that the compound of formula I is other than one of the following compounds: